AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33113452 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Cognitive Behavioral Therapy for Suicide Prevention (BCBT)
Number of subjects: 152
Study 33113452 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 152
Study 35270619 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-Sided Games (SSGs)
Number of subjects: 32
Study 35270619 — intervention group
Group type: COMPARATOR
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 32
Study 34973108 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab + BSC
Number of subjects: 73
Study 34973108 — intervention group
Group type: COMPARATOR
Intervention: BSC alone
Number of subjects: 73
Study 32588803 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi-polysaccharide (ViPS) typhoid vaccine
Number of subjects: 14797
Study 35143747 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Gait Training (RAGT) plus physiotherapy
Number of subjects: 26
Study 35143747 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy alone (Control)
Number of subjects: 26
Study 32314015 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg vaginal dinoprostone
Number of subjects: 200
Study 35771891 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron isomaltoside (20 mg.kg‐1 up to 1000 mg over 30 minutes)
Number of subjects: 40
Study 35771891 — intervention group
Group type: COMPARATOR
Intervention: Usual preoperative care (control)
Number of subjects: 40
Study 32529940 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparent film dressing
Number of subjects: 110
Study 32529940 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 110
Study 34593344 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention involving the use of the PADR-EC ADR score communicated to clinicians and discussed with participants, followed by medication management advice to general practitioners and community pharmacists.
Number of subjects: 0
Study 33491087 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy (HbA1c < 6.2%, blood pressure < 120/75 mm Hg, LDL-cholesterol < 80 mg/dL)
Number of subjects: 0
Study 33491087 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (HbA1c < 6.9%, blood pressure < 130/80 mm Hg, LDL-cholesterol < 120 mg/dL)
Number of subjects: 0
Study 33491087 — intervention group
Group type: EXPERIMENTAL
Intervention: History of smoking at baseline
Number of subjects: 0
Study 33491087 — intervention group
Group type: EXPERIMENTAL
Intervention: FRAX score [%/10 years] at baseline
Number of subjects: 0
Study 33491087 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of pioglitazone at 1 year after randomization
Number of subjects: 0
Study 32004772 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin (multiple oral doses: 20, 40 or 80 mg/day for 7 days)
Number of subjects: 30
Study 32004772 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (single oral dose: 20, 40 or 80 mg)
Number of subjects: 30
Study 35164654 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching group (IES)
Number of subjects: 79
Study 35164654 — intervention group
Group type: COMPARATOR
Intervention: Internal focus group (INT)
Number of subjects: 79
Study 35164654 — intervention group
Group type: COMPARATOR
Intervention: External focus group (EXT)
Number of subjects: 79
Study 35164654 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (INT, EXT, IES)
Number of subjects: 79
Study 34860675 — intervention group
Group type: EXPERIMENTAL
Intervention: ePRO plus usual care
Number of subjects: 142
Study 34860675 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 142
Study 36005281 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL repair using dynamic intraligamentary stabilization (DIS)
Number of subjects: 85
Study 36005281 — intervention group
Group type: COMPARATOR
Intervention: ACL reconstruction with a semitendinosus tendon autograft
Number of subjects: 85
Study 34032727 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (90 mg qd diltiazem sustained-release capsules)
Number of subjects: 63
Study 34032727 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (5 mg tid nicorandil tablets)
Number of subjects: 63
Study 34032727 — intervention group
Group type: COMPARATOR
Intervention: Routine drug treatments (aspirin, atorvastatin, betaloc ZOK, perindopril, and isosorbidemononitrate sustained-release tablets)
Number of subjects: 63
Study 32854772 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg OD Rivaroxaban treatment for 11 to 17 days
Number of subjects: 88
Study 32854772 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 88
Study 35622608 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-point regimen in the lower eyelid
Number of subjects: 23
Study 35622608 — intervention group
Group type: COMPARATOR
Intervention: One-point regimen in the lower eyelid
Number of subjects: 23
Study 35622608 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of the pretarsal segment of the upper eyelid
Number of subjects: 23
Study 34370609 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom exergames and traditional exercise (n=15)
Number of subjects: 31
Study 34370609 — intervention group
Group type: COMPARATOR
Intervention: Traditional exercise (n=16)
Number of subjects: 31
Study 32058465 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocity-framed message
Number of subjects: 7615
Study 32058465 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed message
Number of subjects: 7615
Study 32058465 — intervention group
Group type: COMPARATOR
Intervention: Peer-framed message
Number of subjects: 7615
Study 32058465 — intervention group
Group type: COMPARATOR
Intervention: Gain-framed message
Number of subjects: 7615
Study 32058465 — intervention group
Group type: COMPARATOR
Intervention: Reciprocity-framed message + Peer message
Number of subjects: 7615
Study 33107033 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related changes in geometric parameters of middle cerebral artery bifurcations
Number of subjects: 200
Study 33107033 — intervention group
Group type: COMPARATOR
Intervention: Comparison of geometric parameters between genders
Number of subjects: 200
Study 33107033 — intervention group
Group type: COMPARATOR
Intervention: Non-equal-diameter branches
Number of subjects: 200
Study 32556710 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback therapy in addition to standard urotherapy
Number of subjects: 57
Study 32556710 — intervention group
Group type: COMPARATOR
Intervention: Standard urotherapy
Number of subjects: 57
Study 35640494 — intervention group
Group type: COMPARATOR
Intervention: Standard labels
Number of subjects: 66
Study 35640494 — intervention group
Group type: EXPERIMENTAL
Intervention: Linguistically enhanced labels
Number of subjects: 66
Study 35640494 — intervention group
Group type: EXPERIMENTAL
Intervention: Linguistically and graphically enhanced labels
Number of subjects: 66
Study 33766811 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenapanor plus binder
Number of subjects: 236
Study 33766811 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus binder
Number of subjects: 236
Study 35200551 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadoxetic acid-enhanced dynamic MRI
Number of subjects: 538
Study 35200551 — intervention group
Group type: COMPARATOR
Intervention: Contrast-enhanced computed tomography (CT)
Number of subjects: 538
Study 34535642 — intervention group
Group type: EXPERIMENTAL
Intervention: CeVICA engineered nanobodies against SARS-CoV-2 RBD
Number of subjects: 1011
Study 34535642 — intervention group
Group type: EXPERIMENTAL
Intervention: Affinity maturation and multivalency engineering of nanobodies
Number of subjects: 1011
Study 35572148 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar vermis iTBS (600 pulses)
Number of subjects: 40
Study 35572148 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 40
Study 32589153 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobbstop mobile app
Number of subjects: 773
Study 32589153 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobbstop mobile app (regular and correct use)
Number of subjects: 773
Study 35072219 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia
Number of subjects: 156
Study 35072219 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 156
Study 34816762 — intervention group
Group type: EXPERIMENTAL
Intervention: MN-166 (ibudilast)
Number of subjects: 0
Study 34816762 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 34085883 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block (ESPB)
Number of subjects: 64
Study 34085883 — intervention group
Group type: COMPARATOR
Intervention: Subcostal Transversus Abdominis Plane Block (STAPB)
Number of subjects: 64
Study 34225724 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency level repositioning intervention
Number of subjects: 3300
Study 34225724 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (control group)
Number of subjects: 3300
Study 36354255 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemia-free liver transplantation (IFLT)
Number of subjects: 0
Study 36354255 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory results from IFLT grafts
Number of subjects: 0
Study 33233717 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended cognitive–behavioral intervention (integrating face‐to‐face sessions with a web‐based program)
Number of subjects: 0
Study 33233717 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment for postpartum depression provided in healthcare centers
Number of subjects: 0
Study 33233717 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended cognitive–behavioral intervention
Number of subjects: 0
Study 33233717 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment for postpartum depression
Number of subjects: 0
Study 34858564 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality nursing intervention
Number of subjects: 74
Study 34858564 — intervention group
Group type: COMPARATOR
Intervention: Control group (no quality nursing intervention)
Number of subjects: 74
Study 32303437 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-sided tumors (KRAS wild-type)
Number of subjects: 700
Study 32303437 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-sided tumors (KRAS mutant)
Number of subjects: 700
Study 32303437 — intervention group
Group type: EXPERIMENTAL
Intervention: KRAS mutation
Number of subjects: 700
Study 32303437 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkaline phosphatase
Number of subjects: 700
Study 32303437 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic factors
Number of subjects: 700
Study 32303437 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-EGFR agents exposure
Number of subjects: 700
Study 35322693 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive end expiratory pressure of 5cm H2O (Group II)
Number of subjects: 2
Study 35322693 — intervention group
Group type: COMPARATOR
Intervention: No positive end expiratory pressure (Group I)
Number of subjects: 2
Study 34313765 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Number of subjects: 326
Study 34313765 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 326
Study 32304482 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led computerized cognitive training (CCT) for 4 weeks
Number of subjects: 15
Study 32304482 — intervention group
Group type: COMPARATOR
Intervention: Occupational therapist-led computerized cognitive training (CCT) for 4 weeks
Number of subjects: 15
Study 33097365 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice treatment with physiologic voice therapy plus vocal hygiene program (n = 17)
Number of subjects: 34
Study 33097365 — intervention group
Group type: COMPARATOR
Intervention: Vocal hygiene program only (n = 17)
Number of subjects: 34
Study 33988941 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy and sacroiliac joints home‐based exercise program
Number of subjects: 69
Study 33988941 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacroiliac joints manual therapy and home‐based lumbar exercise program
Number of subjects: 69
Study 33988941 — intervention group
Group type: EXPERIMENTAL
Intervention: Home‐based lumbar exercise program
Number of subjects: 69
Study 32278735 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic kidney disease defined by an eGFR < 60 mL/min/1.73 m2
Number of subjects: 182
Study 32278735 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 182
Study 32278735 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 182
Study 32278735 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrotoxic treatment
Number of subjects: 182
Study 35916347 — intervention group
Group type: EXPERIMENTAL
Intervention: SIGNALS score (0-8 points based on various clinical factors)
Number of subjects: 1542
Study 35916347 — intervention group
Group type: EXPERIMENTAL
Intervention: SIGNALS score (training cohort)
Number of subjects: 1542
Study 35916347 — intervention group
Group type: EXPERIMENTAL
Intervention: SIGNALS score (validation cohort)
Number of subjects: 1542
Study 34582480 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet mitochondrial respiration and CoQ10 levels in RA patients
Number of subjects: 21
Study 34582480 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 21
Study 33203167 — intervention group
Group type: EXPERIMENTAL
Intervention: Full feeding
Number of subjects: 0
Study 33203167 — intervention group
Group type: EXPERIMENTAL
Intervention: Trophic feeding
Number of subjects: 0
Study 33203167 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35482329 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity cycling
Number of subjects: 114
Study 35482329 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-intensity cycling
Number of subjects: 114
Study 35482329 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 114
Study 34725044 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured, theoretically driven, self-management group education programme with motivational text-message support
Number of subjects: 353
Study 34725044 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 353
Study 35562205 — intervention group
Group type: EXPERIMENTAL
Intervention: CN-105 (0.03 mg/kg)
Number of subjects: 40
Study 35562205 — intervention group
Group type: EXPERIMENTAL
Intervention: CN-105 (0.1 mg/kg)
Number of subjects: 40
Study 35562205 — intervention group
Group type: EXPERIMENTAL
Intervention: CN-105 (0.3 mg/kg)
Number of subjects: 40
Study 35562205 — intervention group
Group type: EXPERIMENTAL
Intervention: CN-105 (1 mg/kg)
Number of subjects: 40
Study 35562205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 33551165 — intervention group
Group type: COMPARATOR
Intervention: 0 g/d of YS powder
Number of subjects: 40
Study 33551165 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/d of YS powder
Number of subjects: 40
Study 33551165 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g/d of YS powder
Number of subjects: 40
Study 33551165 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 g/d of YS powder
Number of subjects: 40
Study 33305817 — intervention group
Group type: EXPERIMENTAL
Intervention: daridorexant 50 mg
Number of subjects: 28
Study 33305817 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study 35168036 — intervention group
Group type: EXPERIMENTAL
Intervention: SIE under normoxia
Number of subjects: 10
Study 35168036 — intervention group
Group type: COMPARATOR
Intervention: SIE under systemic hyperoxia (FiO2 = 60%)
Number of subjects: 10
Study 34363552 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative assessment using the ATOP scale
Number of subjects: 316
Study 34363552 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative assessment using the ATOP scale 1 year after surgery
Number of subjects: 316
Study 34363552 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement invariance tests
Number of subjects: 316
Study 36134520 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted sleep duration
Number of subjects: 396858
Study 36134520 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted short sleep duration
Number of subjects: 396858
Study 36134520 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted long sleep duration
Number of subjects: 396858
Study 32696600 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily step count during quarantine
Number of subjects: 26
Study 32696600 — intervention group
Group type: EXPERIMENTAL
Intervention: Average daily step count before and during quarantine
Number of subjects: 26
Study 35638548 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront ABVD plus radiation therapy
Number of subjects: 148
Study 35638548 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront escBEACOPP without radiotherapy
Number of subjects: 148
Study 35638548 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline TMTV ≥155 mL
Number of subjects: 148
Study 35638548 — intervention group
Group type: EXPERIMENTAL
Intervention: PET2 response assessment
Number of subjects: 148
Study 35638548 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline TMTV and PET2 response
Number of subjects: 148
Study 33843073 — intervention group
Group type: EXPERIMENTAL
Intervention: Thula Sana intervention
Number of subjects: 64
Study 33843073 — intervention group
Group type: COMPARATOR
Intervention: Normal care (control)
Number of subjects: 64
Study 32481275 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 360
Study 32481275 — intervention group
Group type: EXPERIMENTAL
Intervention: Battlefield Acupuncture (BFA)
Number of subjects: 360
Study 32481275 — intervention group
Group type: COMPARATOR
Intervention: Usual-care wait-list control (WLC)
Number of subjects: 360
Study 33097977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg orally 1 hour before ESP
Number of subjects: 60
Study 33097977 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (single session immediately after ESP)
Number of subjects: 60
Study 33097977 — intervention group
Group type: COMPARATOR
Intervention: Placebo lactose tablets orally 1 hour before ESP
Number of subjects: 60
Study 36251249 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 2257
Study 32024790 — intervention group
Group type: EXPERIMENTAL
Intervention: pH 7.2
Number of subjects: 0
Study 32024790 — intervention group
Group type: EXPERIMENTAL
Intervention: pH 7.3
Number of subjects: 0
Study 32024790 — intervention group
Group type: EXPERIMENTAL
Intervention: pH 7.4
Number of subjects: 0
Study 32812022 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 254
Study 33066789 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic assessment using natural language processing
Number of subjects: 125
Study 33066789 — intervention group
Group type: COMPARATOR
Intervention: Manual rating based on a rubric
Number of subjects: 125
Study 34773489 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Anterior Approach (DAA)
Number of subjects: 20
Study 34773489 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral Approach (PLA)
Number of subjects: 20
Study 36285484 — intervention group
Group type: EXPERIMENTAL
Intervention: Prism adaptation training during standard occupational therapy sessions for three weeks.
Number of subjects: 80
Study 36285484 — intervention group
Group type: COMPARATOR
Intervention: Standard occupational therapy (control group).
Number of subjects: 80
Study 36285484 — intervention group
Group type: EXPERIMENTAL
Intervention: Prism adaptation training (intervention).
Number of subjects: 80
Study 33124670 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative body weight
Number of subjects: 88
Study 33124670 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline lean mass
Number of subjects: 88
Study 33124670 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent gynoid fat
Number of subjects: 88
Study 33124670 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent body fat
Number of subjects: 88
Study 33124670 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin independence
Number of subjects: 88
Study 32945008 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical ablation for atrial fibrillation (AF)
Number of subjects: 259
Study 33449097 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy HDDs
Number of subjects: 319
Study 33449097 — intervention group
Group type: COMPARATOR
Intervention: Clinically noted HDDs
Number of subjects: 319
Study 36219243 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Early Mobilization Group (VEMG) - 51 patients received VEMG within 24 hours of the ictus
Number of subjects: 104
Study 36219243 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Group (UCG) - 53 patients received usual care with mobilization 24 hours after the ictus
Number of subjects: 104
Study 32885583 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 44
Study 32885583 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 44
Study 34612785 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Mindfulness Meditation (BMM)
Number of subjects: 64
Study 34612785 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study 32993818 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandwich dietary pattern (cold cuts, refined grains, cheese and miscellaneous)
Number of subjects: 1845
Study 32993818 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy dietary pattern (produce and whole grains)
Number of subjects: 1845
Study 32993818 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhealthy dietary pattern (fried food, savoury snacks and desserts)
Number of subjects: 1845
Study 32993818 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy- and sugar-sweetened beverage-based dietary pattern
Number of subjects: 1845
Study 32993818 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Mexican dietary pattern
Number of subjects: 1845
Study 32290122 — intervention group
Group type: EXPERIMENTAL
Intervention: GS mint (4 mg of gymnemic acids)
Number of subjects: 56